FIELD: chemistry.
SUBSTANCE: claimed invention relates to formula I compounds and their pharmaceutically acceptable salts. Compounds of claimed invention can be applied as medication for treating disorders induced by cell proliferation or mediated by nucleus receptors. In general formula 
, A represents phenyl or unsaturated monocyclic 6-member group, containing nitrogen atom as heteroatom; B represents phenyl group; Z represents bond; Y represents group -CO-NH-CH2-; R1, R2, R3 independently represent hydrogen; R4 represents aminogroup; and one of X1, X2 , X3 or X4 represents halogen atom, while other ones of X1, X2, X3 or X4 independently represent hydrogen atom.
EFFECT: invention also relates to method of obtaining, pharmaceutical compositions, to application of invention compounds, as well as to formula IV compound.
22 cl, 1 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NAPHTHALENE CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE AND HISTONE DEACETYLASE INHIBITORS, METHODS FOR PREPARING AND USING THEM | 2010 |
|
RU2497809C2 |
| BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETILASE INHIBITORS | 2006 |
|
RU2448965C2 |
| MACROCYCLIC COMPOUNDS, APPLIED AS HISTONE DEACETYLASE INHIBITORS | 2011 |
|
RU2565076C2 |
| HDAC INHIBITORS | 2014 |
|
RU2665554C2 |
| 4-(3-((2-ADAMANTYL)AMINO)-3-OXOPROP-1-EN-1-YL)-N-HYDROXYBENZAMIDE - A NEW DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2022 |
|
RU2783995C1 |
| HETEROCYCLIC ALKYL DERIVATIVE COMPOUNDS AS THE HISTONE DEACETYLASE SELECTIVE INHIBITORS AND CONTAINING THEM PHARMACEUTICAL COMPOSITIONS | 2016 |
|
RU2683022C1 |
| METHODS OF REDUCING CACHEXIA ASSOCIATED WITH CANCER | 2014 |
|
RU2692785C1 |
| HISTONE DEACETYLASE INHIBITORS | 2008 |
|
RU2453536C2 |
| HYDROXAMIC ACIDS, DERIVATIVES OF 4-AMINOQUINAZOLINE-7-CARBOXYLIC ACID AS INHIBITORS OF HISTONE DEACETYLASE, AND METHOD FOR SYNTHESIS THEREOF | 2021 |
|
RU2779981C1 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
